Latest Hotspot

Fresenius Kabi introduces Tyenne*, the inaugural EU-sanctioned tocilizumab biosimilar

9 November 2023
3 min read

Fresenius Kabi, a worldwide healthcare firm with a focus on biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for severe and long-term illnesses, made an announcement about the introduction of Tyenne®, its tocilizumab biosimilar which references the RoActemra® (tocilizumab) in the European Union.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Tyenne® is recognized as Europe's first accessible tocilizumab biosimilar, offering treatment for a variety of inflammatory and immune conditions, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome, as well as providing assistance in treating COVID-19. 

Tyenne® is the third biosimilar from Fresenius Kabi that gained approval and hit the European market. It presents a versatile suite of easy-to-use subcutaneous and intravenous delivery methods to patients and healthcare professionals. 

Fresenius Kabi's CEO, Pierluigi Antonelli, commented, “The roll-out validates our Vision 2026 expansion tactic to supply indispensable treatment alternatives to worldwide patients and healthcare providers. Our biopharma portfolio continually expands, made evident by the introduction of tocilizumab on the European scene, underscoring our steady growth trajectory. Our standing as the inaugural healthcare company to present a tocilizumab biosimilar in the EU displays our determination to lead the biopharma sector.” 

Dr. Michael Schönhofen, President of Fresenius Kabi Biopharmaceuticals, added, “We take great pride in being the pioneers in furnishing an economic, top-quality, secure, and alternate tocilizumab therapy solution for patients suffering from inflammatory and immune disorders and healthcare professionals. 

Tyenne®, offering both subcutaneous and intravenous routes, stands to revolutionize the treatment scene, augment patient results, and alleviate the financial stress on healthcare systems and patients."

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of November 9, 2023, there are 35 investigational drugs for the IL-6RA target, including 56 indications, 72 R&D institutions involved, with related clinical trials reaching 794, and as many as 1626 patents.

Tyenne® (tocilizumab), is a biosimilar to the reference medicinal product RoActemra®, a prescription medicine called an Interleukin-6 (IL-6) receptor antagonist. Tocilizumab is a biological therapy approved in the EU for use in the treatment of various inflammatory and immune mediated conditions, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis. 

图形用户界面, 文本, 应用程序

描述已自动生成

Satralizumab Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Satralizumab Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
20 November 2023
This article summarized the latest R&D progress of Satralizumab, the Mechanism of Action for Satralizumab, and the drug target R&D trends for Satralizumab.
Read →
 Unleashing the Power of Sevelamer Hydrochloride: A Comprehensive Review on R&D Breakthroughs
Drug Insights
4 min read
Unleashing the Power of Sevelamer Hydrochloride: A Comprehensive Review on R&D Breakthroughs
20 November 2023
This article summarized the latest R&D progress of Sevelamer Hydrochloride, the Mechanism of Action for Sevelamer Hydrochloride, and the drug target R&D trends for Sevelamer Hydrochloride.
Read →
A Comprehensive Review of Spiramycin's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Spiramycin's R&D Innovations and Drug Target Mechanism
20 November 2023
This article summarized the latest R&D progress of Spiramycin, the Mechanism of Action for Spiramycin, and the drug target R&D trends for Spiramycin.
Read →
Pharmaceutical Insights: Sulfamethazine's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Pharmaceutical Insights: Sulfamethazine's R&D Progress and its Mechanism of Action on Drug Target
20 November 2023
This article summarized the latest R&D progress of Sulfamethazine, the Mechanism of Action for Sulfamethazine, and the drug target R&D trends for Sulfamethazine.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.